Lazard acted as the exclusive financial advisor to Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor. Evercore acted as the exclusive financial advisor ...

Shares of Hims & Hers rose 7.59 percent on Wednesday to finish at $33.88 apiece as investors resorted to bargain-hunting ...

After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Russia has a new business elite and radically altered marketplace—and it’s done away with key legal protections.

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...